DR. GERALD BELOPOLSKY MD
Prescription History 1861473621
Internal Medicine - Pulmonary Disease in Mountain Home, AR


Quality Rating: 95.53 out of 100 score

NPI Status: Active since November 09, 2005

Contact Information

628 HOSPITAL DR STE 3A
MOUNTAIN HOME, AR
ZIP 72653
Phone: (870) 425-1787

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. GERALD BELOPOLSKY MD, an active Pulmonary Disease specialist practicing in Mountain Home, AR. Our medical registry currently tracks 25 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 1,405 documented patient claims. Among these therapy options, the most frequently utilized medication is Trelegy Ellipta, which accounts for 441 claims alone.


Advair Diskus

Generic Formulation: Fluticasone Propion/SalmeterolSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 30
30-Day Fills 30.0
Days Supply 900
AR State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills26.5
Peer Average Days Supply794
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 36.4% more claims than the standard regional baseline profile for AR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $14,243.93 across this reporting matrix range.

Provider Avg Cost Per Claim

$474.80

State Avg Cost Per Claim

$512.18

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: fluticasone and salmeterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Salmeterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as salmeterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Advair Hfa

Generic Formulation: Fluticasone Propion/SalmeterolSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 12
30-Day Fills 17.0
Days Supply 510
AR State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills23.7
Peer Average Days Supply710
Conservative Utilization

This provider writes prescriptions for this formulation 40.0% less frequently than the standard regional baseline metric for practitioners inside AR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $5,699.10 across this reporting matrix range.

Provider Avg Cost Per Claim

$474.93

State Avg Cost Per Claim

$558.52

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: fluticasone and salmeterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Salmeterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as salmeterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Albuterol Sulfate Hfa

Generic Formulation: Albuterol SulfateSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 82
30-Day Fills 92.0
Days Supply 2,056
AR State Average Benchmarks
Peer Average Claims70.0
Peer Average 30-Day Fills83.8
Peer Average Days Supply2,091
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across AR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,525.66 across this reporting matrix range.

Provider Avg Cost Per Claim

$43.00

State Avg Cost Per Claim

$47.60

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.

Therapeutic Applications

Albuterol (also known as salbutamol) is used to treat wheezing and shortness of breath caused by breathing problems such as asthma. It is a quick-relief medication. Albuterol belongs to a class of drugs known as bronchodilators. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school.

Anoro Ellipta

Generic Formulation: Umeclidinium Brm/Vilanterol TrSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 143
30-Day Fills 147.0
Days Supply 4,410
AR State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills34.4
Peer Average Days Supply1,029
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 410.7% higher than the standard regional baseline profile for AR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $67,419.91 across this reporting matrix range.

Provider Avg Cost Per Claim

$471.47

State Avg Cost Per Claim

$580.15

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you stay active. This inhaler contains 2 medications: umeclidinium and vilanterol. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Umeclidinium belongs to a class of drugs known as anticholinergics. Vilanterol belongs to the class of drugs known as long-acting beta agonists (LABAs). Both drugs are also known as bronchodilators. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed. Umeclidinium/vilanterol is not approved to treat asthma. People with asthma using long-acting inhaled beta agonists (such as vilanterol) without also using an inhaled corticosteroid may have an increased risk of serious (sometimes fatal) breathing problems.

Arnuity Ellipta

Generic Formulation: Fluticasone FuroateSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 21
30-Day Fills 27.0
Days Supply 810
AR State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills29.5
Peer Average Days Supply883
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across AR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $6,133.38 across this reporting matrix range.

Provider Avg Cost Per Claim

$292.07

State Avg Cost Per Claim

$279.44

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Fluticasone is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma. Controlling symptoms of asthma helps you maintain your normal activities and decreases time lost from work or school. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling (inflammation) of the airways in the lungs to make breathing easier. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Azithromycin

Generic Formulation: AzithromycinSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 45
30-Day Fills 47.9
Days Supply 1,257
AR State Average Benchmarks
Peer Average Claims44.0
Peer Average 30-Day Fills45.2
Peer Average Days Supply296
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across AR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $509.17 across this reporting matrix range.

Provider Avg Cost Per Claim

$11.31

State Avg Cost Per Claim

$9.74

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.

Therapeutic Applications

This medication is used to treat certain eye infections. It is a macrolide antibiotic that works by stopping the growth of bacteria. This medication treats only bacterial eye infections. It will not work for other types of eye infections. Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Breo Ellipta

Generic Formulation: Fluticasone/VilanterolSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 102
30-Day Fills 120.0
Days Supply 3,600
AR State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills38.4
Peer Average Days Supply1,149
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 229.0% higher than the standard regional baseline profile for AR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $47,177.44 across this reporting matrix range.

Provider Avg Cost Per Claim

$462.52

State Avg Cost Per Claim

$501.64

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to prevent and decrease symptoms (wheezing and trouble breathing) caused by asthma and ongoing lung disease (chronic obstructive pulmonary disease-COPD, including chronic bronchitis and emphysema). This inhaler contains 2 medications: fluticasone and vilanterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the swelling of the airways in the lungs to make breathing easier. Vilanterol belongs to a class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. When used alone, long-acting beta agonists (like vilanterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Breztri Aerosphere

Generic Formulation: Budesonide/Glycopyr/FormoterolSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 26
30-Day Fills 30.0
Days Supply 900
AR State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills33.2
Peer Average Days Supply993
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across AR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $20,212.59 across this reporting matrix range.

Provider Avg Cost Per Claim

$777.41

State Avg Cost Per Claim

$760.07

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you maintain your normal activities and decreases time lost from work or school. This inhaler contains 3 medications: budesonide, glycopyrrolate, and formoterol. Budesonide works by reducing the irritation and swelling of the airways. Budesonide belongs to a class of drugs known as corticosteroids. Glycopyrrolate and formoterol work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Glycopyrrolate belongs to a class of drugs known as anticholinergics. Formoterol belongs to the class of drugs known as long-acting beta agonists (LABAs). Both drugs are also known as bronchodilators. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden breathing problems. If sudden shortness of breath occurs, use your quick-relief inhaler as prescribed. This medication is not approved to treat asthma.

Combivent Respimat

Generic Formulation: Ipratropium/Albuterol SulfateSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 30
30-Day Fills 30.0
Days Supply 900
AR State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills22.6
Peer Average Days Supply655
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 57.9% higher than the standard regional baseline profile for AR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $13,901.56 across this reporting matrix range.

Provider Avg Cost Per Claim

$463.39

State Avg Cost Per Claim

$594.19

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to treat and prevent symptoms (wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes bronchitis and emphysema). This product contains 2 medications: ipratropium and albuterol (also known as salbutamol). Both drugs work by relaxing the muscles around the airways so that the airways open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school.

Doxycycline Monohydrate

Generic Formulation: Doxycycline MonohydrateSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 22
30-Day Fills 22.0
Days Supply 437
AR State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills24.4
Peer Average Days Supply267
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across AR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $227.16 across this reporting matrix range.

Provider Avg Cost Per Claim

$10.33

State Avg Cost Per Claim

$19.18

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A plant family of the order Dipsacales, subclass Asteridae, class Magnoliopsida. Members of this family are sometimes classified in CAPRIFOLIACEAE.

Therapeutic Applications

This medication is used to treat a certain type of skin condition called rosacea. It helps to reduce the number of pimples and bumps on the face, but it may not decrease redness. It works by reducing skin inflammation caused by rosacea. Although doxycycline belongs to the class of antibiotics known as tetracyclines, this product does not work as an antibiotic because it does not stop the growth of bacteria. Do not use this product to treat any infection, including viral infections (such as the common cold, flu). Use this medication only as prescribed by your doctor.

Fluticasone Propionate

Generic Formulation: Fluticasone PropionateSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 58
30-Day Fills 62.0
Days Supply 1,860
AR State Average Benchmarks
Peer Average Claims56.0
Peer Average 30-Day Fills84.8
Peer Average Days Supply2,534
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across AR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $656.89 across this reporting matrix range.

Provider Avg Cost Per Claim

$11.33

State Avg Cost Per Claim

$17.17

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A STEROID with GLUCOCORTICOID RECEPTOR activity that is used to manage the symptoms of ASTHMA; ALLERGIC RHINITIS, and ATOPIC DERMATITIS.

Therapeutic Applications

Fluticasone is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma. Controlling symptoms of asthma helps you maintain your normal activities and decreases time lost from work or school. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling (inflammation) of the airways in the lungs to make breathing easier. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Fluticasone-Salmeterol

Generic Formulation: Fluticasone Propion/SalmeterolSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 12
30-Day Fills 20.0
Days Supply 598
AR State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills25.7
Peer Average Days Supply769
Conservative Utilization

This provider writes prescriptions for this formulation 36.8% less frequently than the standard regional baseline metric for practitioners inside AR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,700.69 across this reporting matrix range.

Provider Avg Cost Per Claim

$225.06

State Avg Cost Per Claim

$252.32

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: fluticasone and salmeterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Salmeterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as salmeterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Furosemide

Generic Formulation: FurosemideSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 18
30-Day Fills 18.0
Days Supply 540
AR State Average Benchmarks
Peer Average Claims106.0
Peer Average 30-Day Fills181.7
Peer Average Days Supply5,290
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 83.0% less volume than the regional standard for practitioners inside AR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $63.29 across this reporting matrix range.

Provider Avg Cost Per Claim

$3.52

State Avg Cost Per Claim

$5.88

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY.

Therapeutic Applications

Furosemide is used to reduce extra fluid in the body (edema) caused by conditions such as heart failure, liver disease, and kidney disease. This can lessen symptoms such as shortness of breath and swelling in your arms, legs, and abdomen. This drug is also used to treat high blood pressure. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. Furosemide is a water pill (diuretic) that causes you to make more urine. This helps your body get rid of extra water and salt.

Incruse Ellipta

Generic Formulation: Umeclidinium BromideSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 30
30-Day Fills 30.0
Days Supply 900
AR State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills27.6
Peer Average Days Supply825
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 30.4% more claims than the standard regional baseline profile for AR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $10,948.12 across this reporting matrix range.

Provider Avg Cost Per Claim

$364.94

State Avg Cost Per Claim

$451.56

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Umeclidinium is used to control and prevent symptoms (such as wheezing, shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes bronchitis and emphysema). It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Umeclidinium belongs to a class of drugs known as anticholinergics. Controlling symptoms of breathing problems can decrease time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If wheezing or sudden shortness of breath occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Montelukast Sodium

Generic Formulation: Montelukast SodiumSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 34
30-Day Fills 52.0
Days Supply 1,550
AR State Average Benchmarks
Peer Average Claims59.0
Peer Average 30-Day Fills112.6
Peer Average Days Supply3,350
Conservative Utilization

This provider writes prescriptions for this formulation 42.4% less frequently than the standard regional baseline metric for practitioners inside AR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $705.44 across this reporting matrix range.

Provider Avg Cost Per Claim

$20.75

State Avg Cost Per Claim

$18.27

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Montelukast is used to control and prevent symptoms caused by asthma (such as wheezing and shortness of breath). It is also used before exercise to prevent breathing problems during exercise (bronchospasm). This medication can help decrease the number of times you need to use your quick relief inhaler. Montelukast is also used to relieve symptoms of hay fever and allergic rhinitis (such as sneezing, stuffy/runny/itchy nose). Since there are other allergy medications that may be safer (see also Warning section), this medication should be used for this condition only when you cannot take other allergy medications or they do not work well. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks or breathing problems. If an asthma attack or sudden shortness of breath occurs, use your quick-relief inhaler as prescribed. This drug works by blocking certain natural substances (leukotrienes) that may cause or worsen asthma and allergies. It helps make breathing easier by reducing swelling (inflammation) in the airways.

Ofev

Generic Formulation: Nintedanib EsylateSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 32
30-Day Fills 32.0
Days Supply 960
AR State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills28.6
Peer Average Days Supply855
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across AR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $396,836.19 across this reporting matrix range.

Provider Avg Cost Per Claim

$12,401.13

State Avg Cost Per Claim

$12,381.15

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain types of lung disease (idiopathic pulmonary fibrosis- IPF, interstitial lung disease). Both types of lung disease scar and stiffen your lungs, making it hard to breathe. Nintedanib may help slow down the worsening of your lung disease.

Pirfenidone

Generic Formulation: PirfenidoneSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 390
AR State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills17.8
Peer Average Days Supply533
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across AR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $116,147.14 across this reporting matrix range.

Provider Avg Cost Per Claim

$8,934.40

State Avg Cost Per Claim

$5,147.71

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Pirfenidone is used to treat a certain lung disease called idiopathic pulmonary fibrosis (IPF). This disease causes the lungs to get scarred and become stiff, making it hard to breathe. Pirfenidone may help slow down the worsening of your IPF.

Prednisone

Generic Formulation: PrednisoneSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 68
30-Day Fills 75.5
Days Supply 1,658
AR State Average Benchmarks
Peer Average Claims50.0
Peer Average 30-Day Fills57.4
Peer Average Days Supply961
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 36.0% more claims than the standard regional baseline profile for AR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $367.29 across this reporting matrix range.

Provider Avg Cost Per Claim

$5.40

State Avg Cost Per Claim

$7.13

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.

Therapeutic Applications

Prednisone is used to treat conditions such as arthritis, blood disorders, breathing problems, severe allergies, skin diseases, cancer, eye problems, and immune system disorders. Prednisone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Roflumilast

Generic Formulation: RoflumilastSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 26
30-Day Fills 26.0
Days Supply 772
AR State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills26.0
Peer Average Days Supply772
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 36.8% more claims than the standard regional baseline profile for AR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $4,979.83 across this reporting matrix range.

Provider Avg Cost Per Claim

$191.53

State Avg Cost Per Claim

$264.39

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Roflumilast is used to control and prevent symptoms (wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD which includes bronchitis). It should be used along with other medications (bronchodilators such as salmeterol, ipratropium) to treat COPD. It works by reducing the irritation and swelling of the airways. Controlling symptoms of breathing problems can decrease time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath or wheezing. If sudden breathing problems occur, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Spiriva Respimat

Generic Formulation: Tiotropium BromideSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 330
AR State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills35.7
Peer Average Days Supply1,069
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 59.3% less volume than the regional standard for practitioners inside AR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $5,740.96 across this reporting matrix range.

Provider Avg Cost Per Claim

$521.91

State Avg Cost Per Claim

$682.94

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A scopolamine derivative and CHOLINERGIC ANTAGONIST that functions as a BRONCHODILATOR AGENT. It is used in the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

Therapeutic Applications

Tiotropium is used to control and prevent symptoms (such as wheezing, shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD which includes bronchitis and emphysema). It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Tiotropium belongs to a class of drugs known as anticholinergics. Controlling symptoms of breathing problems can decrease time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden breathing problems. If wheezing or sudden shortness of breath occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Stiolto Respimat

Generic Formulation: Tiotropium Br/Olodaterol HclSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 103
30-Day Fills 115.0
Days Supply 3,448
AR State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills37.0
Peer Average Days Supply1,109
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 255.2% higher than the standard regional baseline profile for AR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $53,586.01 across this reporting matrix range.

Provider Avg Cost Per Claim

$520.25

State Avg Cost Per Claim

$611.30

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you stay active. This inhaler contains 2 medications: tiotropium and olodaterol. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Tiotropium belongs to a class of drugs known as anticholinergics. Olodaterol belongs to the class of drugs known as long-acting inhaled beta-agonists (LABAs). Both drugs are also known as bronchodilators. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed. Tiotropium/olodaterol is not approved to treat asthma. People with asthma using long-acting inhaled beta agonists (such as olodaterol) without also using an inhaled corticosteroid may have an increased risk of serious (sometimes fatal) breathing problems.

Sulfamethoxazole-Trimethoprim

Generic Formulation: Sulfamethoxazole/TrimethoprimSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.3
Days Supply 354
AR State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills27.7
Peer Average Days Supply322
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 53.8% less volume than the regional standard for practitioners inside AR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $67.19 across this reporting matrix range.

Provider Avg Cost Per Claim

$5.60

State Avg Cost Per Claim

$6.78

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A drug combination with broad-spectrum antibacterial activity against both gram-positive and gram-negative organisms. It is effective in the treatment of many infections, including PNEUMOCYSTIS PNEUMONIA in AIDS.

Therapeutic Applications

This medication is a combination of two antibiotics: sulfamethoxazole and trimethoprim. It is used to treat a wide variety of bacterial infections (such as middle ear, urine, respiratory, and intestinal infections). It is also used to prevent and treat a certain type of pneumonia (pneumocystis-type). This medication should not be used by children less than 2 months of age due to the risk of serious side effects. This medication treats only certain types of infections. It will not work for viral infections (such as flu). Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Symbicort

Generic Formulation: Budesonide/Formoterol FumarateSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 16
30-Day Fills 18.0
Days Supply 540
AR State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills43.1
Peer Average Days Supply1,291
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 51.5% less volume than the regional standard for practitioners inside AR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $6,315.37 across this reporting matrix range.

Provider Avg Cost Per Claim

$394.71

State Avg Cost Per Claim

$507.81

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pharmaceutical preparation of budesonide and formoterol fumarate that is used as an ANTI-ASTHMATIC AGENT and for the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: budesonide and formoterol. Budesonide belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Formoterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as formoterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. Before using this medication, it is important to learn how to use it properly. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed. See also How to Use section.

Trelegy Ellipta

Generic Formulation: Fluticasone/Umeclidin/VilanterSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 441
30-Day Fills 474.0
Days Supply 14,220
AR State Average Benchmarks
Peer Average Claims46.0
Peer Average 30-Day Fills58.2
Peer Average Days Supply1,742
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 858.7% higher than the standard regional baseline profile for AR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $300,710.08 across this reporting matrix range.

Provider Avg Cost Per Claim

$681.88

State Avg Cost Per Claim

$829.51

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma and ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you stay active. This inhaler contains 3 medications: fluticasone, umeclidinium, and vilanterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling of the airways in the lungs to make breathing easier. Umeclidinium belongs to a class of drugs known as anticholinergics and vilanterol is a LABA medication. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Both drugs are also known as bronchodilators. When used alone, long-acting beta agonists (such as vilanterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination products containing both an inhaled corticosteroid and long-acting beta agonist, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with two asthma-control medications (such as inhaled corticosteroid and long-acting beta agonist) or if your symptoms need combination treatment. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed.

Ventolin Hfa

Generic Formulation: Albuterol SulfateSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 18
30-Day Fills 18.0
Days Supply 395
AR State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills30.4
Peer Average Days Supply753
Conservative Utilization

This provider writes prescriptions for this formulation 33.3% less frequently than the standard regional baseline metric for practitioners inside AR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,044.97 across this reporting matrix range.

Provider Avg Cost Per Claim

$58.05

State Avg Cost Per Claim

$73.77

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.

Therapeutic Applications

Albuterol (also known as salbutamol) is used to treat wheezing and shortness of breath caused by breathing problems such as asthma. It is a quick-relief medication. Albuterol belongs to a class of drugs known as bronchodilators. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. GERALD BELOPOLSKY MD provides transparency into local medical care patterns within Mountain Home, AR.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Pulmonary Disease** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.